ATE175664T1 - Kristalline, polymorphische form von (s,s,s)-n-(1-(2-carboxy-3-(n2-mesyllysylamino)p opyl>-1- cyclopentylcarbonyl)tyrosin - Google Patents

Kristalline, polymorphische form von (s,s,s)-n-(1-(2-carboxy-3-(n2-mesyllysylamino)p opyl>-1- cyclopentylcarbonyl)tyrosin

Info

Publication number
ATE175664T1
ATE175664T1 AT95900719T AT95900719T ATE175664T1 AT E175664 T1 ATE175664 T1 AT E175664T1 AT 95900719 T AT95900719 T AT 95900719T AT 95900719 T AT95900719 T AT 95900719T AT E175664 T1 ATE175664 T1 AT E175664T1
Authority
AT
Austria
Prior art keywords
polymorphic form
crystalline
mesyllysylamino
opyl
cyclopentylcarbonyl
Prior art date
Application number
AT95900719T
Other languages
English (en)
Inventor
Peter James Dunn
Michael Leslie Hughes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of ATE175664T1 publication Critical patent/ATE175664T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
AT95900719T 1993-12-04 1994-11-09 Kristalline, polymorphische form von (s,s,s)-n-(1-(2-carboxy-3-(n2-mesyllysylamino)p opyl>-1- cyclopentylcarbonyl)tyrosin ATE175664T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives

Publications (1)

Publication Number Publication Date
ATE175664T1 true ATE175664T1 (de) 1999-01-15

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900719T ATE175664T1 (de) 1993-12-04 1994-11-09 Kristalline, polymorphische form von (s,s,s)-n-(1-(2-carboxy-3-(n2-mesyllysylamino)p opyl>-1- cyclopentylcarbonyl)tyrosin

Country Status (26)

Country Link
US (1) US6180665B1 (de)
EP (1) EP0731787B1 (de)
JP (1) JP2701988B2 (de)
KR (1) KR100203314B1 (de)
CN (1) CN1068586C (de)
AT (1) ATE175664T1 (de)
CA (1) CA2178085C (de)
CZ (1) CZ296428B6 (de)
DE (1) DE69416003T2 (de)
DK (1) DK0731787T3 (de)
EG (1) EG20562A (de)
ES (1) ES2128031T3 (de)
FI (1) FI120305B (de)
GB (1) GB9324931D0 (de)
GR (1) GR3029590T3 (de)
HU (1) HU225959B1 (de)
IL (1) IL111791A (de)
MY (1) MY115430A (de)
NO (1) NO306714B1 (de)
NZ (1) NZ276087A (de)
PE (1) PE9296A1 (de)
PL (1) PL178559B1 (de)
RU (1) RU2131869C1 (de)
TW (2) TW534901B (de)
WO (1) WO1995015308A1 (de)
ZA (1) ZA949595B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001287405A1 (en) 2000-08-29 2002-03-13 Riverside Forest Products Limited Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
CA2513837A1 (en) * 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
HU9601506D0 (en) 1996-07-29
NO306714B1 (no) 1999-12-13
TW434210B (en) 2001-05-16
DE69416003D1 (en) 1999-02-25
CZ160496A3 (en) 1996-11-13
JPH09500654A (ja) 1997-01-21
ES2128031T3 (es) 1999-05-01
HU225959B1 (en) 2008-01-28
EP0731787B1 (de) 1999-01-13
MY115430A (en) 2003-06-30
PE9296A1 (es) 1996-04-04
RU2131869C1 (ru) 1999-06-20
PL314794A1 (en) 1996-09-30
AU8142494A (en) 1995-06-19
FI962322A (fi) 1996-06-03
EG20562A (en) 1999-08-30
FI962322A0 (fi) 1996-06-03
CZ296428B6 (cs) 2006-03-15
PL178559B1 (pl) 2000-05-31
FI120305B (fi) 2009-09-15
WO1995015308A1 (en) 1995-06-08
KR960706470A (ko) 1996-12-09
NZ276087A (en) 1997-11-24
TW534901B (en) 2003-06-01
KR100203314B1 (ko) 1999-06-15
NO962294L (no) 1996-06-04
HUT74683A (en) 1997-01-28
CA2178085C (en) 2002-09-03
GB9324931D0 (en) 1994-01-26
JP2701988B2 (ja) 1998-01-21
ZA949595B (en) 1996-06-03
IL111791A0 (en) 1995-01-24
NO962294D0 (no) 1996-06-04
IL111791A (en) 2002-09-12
AU684114B2 (en) 1997-12-04
DE69416003T2 (de) 1999-05-27
DK0731787T3 (da) 1999-08-30
CN1142816A (zh) 1997-02-12
CN1068586C (zh) 2001-07-18
CA2178085A1 (en) 1995-06-08
US6180665B1 (en) 2001-01-30
EP0731787A1 (de) 1996-09-18
GR3029590T3 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
DK0687251T3 (da) 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister
BR9806296B1 (pt) compostos de ácido sulfìnico, mistura, composição e uso dos mesmos.
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
ATE343383T1 (de) Hemmer der zelladhäsion
DK0620003T3 (da) Vasopressinantagonist og oxytocinantagonist
ATE206402T1 (de) 3-acylaminobenzazepine
DE50209545D1 (de) Flüssigkristallines medium
DK0619806T3 (da) Fremstilling af substituerede piperidiner
ATE175664T1 (de) Kristalline, polymorphische form von (s,s,s)-n-(1-(2-carboxy-3-(n2-mesyllysylamino)p opyl>-1- cyclopentylcarbonyl)tyrosin
DK0745081T3 (da) Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
DE69827614D1 (de) Chinoxalindionen
KR970701188A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ACE)의 억제제로서 유용한 신규의 머캅토아세틸아미드 디설파이드 유도체(Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ACE)
WO2000020399A3 (de) Verwendung von substituierten 5-hydroxypyrazolen, neue 5-hydroxypyrazole, verfahren zu deren herstellung, sowie sie enthaltende mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee